Direct comparison
Basket vs Umbrella vs Platform Trials Compared
Basket, umbrella, and platform trials compared: design logic, FDA master protocol guidance, and when to use each, with real trial examples.
Ask about Basket vs Umbrella vs Platform Trials Compared
Answers are drawn from this comparison and the rest of the CASRAI corpus, with a link to every source.
Answers are AI-generated from CASRAI’s own published pages and can be wrong, so check the linked sources before relying on one; your question is logged without personal data — never sold, never used to train a third-party model — to show us what CASRAI is missing, so please do not type personal or confidential details. How we use this
How do Basket Trial, Umbrella Trial, Platform Trial compare side by side?
The table below compares Basket Trial, Umbrella Trial, Platform Trial across 9 procurement-relevant dimensions, from varies along through best suited for.
Side-by-side comparison
| Dimension | Basket Trial | Umbrella Trial | Platform Trial |
|---|---|---|---|
| Varies along | Disease (fixed intervention) | Intervention (fixed disease) | Time (arms added/dropped) |
| Number of interventions | One (or one shared mechanism) | Multiple, fixed roster | Multiple, open-ended roster |
| Number of diseases/populations | Multiple, sharing a biomarker | One | Often one, but not required |
| Arms fixed for trial duration? | Yes, typically | Yes, typically | No -- arms can be added or dropped |
| Control arm | Not always present (single-arm per basket common) | Per-arm or shared, depending on design | Usually a shared, persistent control |
| Typical patient routing | By biomarker/molecular alteration, across histologies | By biomarker, within one disease | By eligibility, into whichever arms are currently open |
| Real-world example | NCI-MATCH (NCI, launched 2015) | Lung-MAP / SWOG S1400 (NCT03851445, launched 2014) | RECOVERY trial (UK, COVID-19) |
| Governing FDA guidance | 2022 finalized oncology master-protocol guidance | 2022 finalized oncology master-protocol guidance | 2022 finalized guidance plus broader draft guidance (reopened for comment June 2026) |
| Best suited for | Tumor-agnostic/biomarker-driven development programs | Head-to-head comparison of candidates in one disease | Long-running research questions with an evolving pipeline (e.g. pandemic response) |
Common questions
Common questions about Basket Trial vs Umbrella Trial vs Platform Trial
Is a platform trial the same as an adaptive trial?
+
No, though they overlap. "Adaptive" describes within-trial statistical rules that let a trial change (sample size, randomization ratios, arm-dropping) based on accumulating data. "Platform" describes the master-protocol structure that allows new arms to enter and old ones to exit over the trial's life. Most platform trials use adaptive statistical elements, but adaptive design and master-protocol type (basket/umbrella/platform) are two different axes.
Can a single trial be both a basket and an umbrella trial?
+
Some master protocols combine elements of both -- for example, testing multiple biomarker-matched interventions (umbrella-like) across multiple diseases sharing those biomarkers (basket-like) within one master protocol. FDA's guidance treats basket and umbrella as the two ends of a spectrum rather than mutually exclusive categories, and a given trial's design documents should specify which structural features apply.
Do basket, umbrella, and platform trials require a single IND?
+
FDA's master-protocol guidance describes a typical approach of a single IND per master protocol, with amendments submitted as arms change, rather than a separate IND for each sub-study -- though the specific regulatory structure depends on the sponsor's submission and should be confirmed with FDA for a given program.
Why is an umbrella trial not called a basket trial if both use biomarkers?
+
The biomarker-matching mechanic is similar, but the axis that varies is opposite: a basket trial holds the intervention fixed and varies the disease/histology (one drug, many diseases sharing a marker); an umbrella trial holds the disease fixed and varies the intervention (one disease, many candidate drugs sorted by marker).
